Please enable Javascript
Raj Satkunasivam, MD, MS, FRCSC
Raj Satkunasivam, MD, MS, FRCSC, Houston Methodist Hospital
Articles by Raj Satkunasivam, MD, MS, FRCSC
How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?
Raj Satkunasivam, MD, MS, FRCSC
Non-Muscle Invasive Urothelial Carcinoma
|
September 8, 2023
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
View More
Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC
Raj Satkunasivam, MD, MS, FRCSC
Muscle Invasive Urothelial Carcinoma
|
August 9, 2023
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
View More
Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches for Local, Distant Control
Raj Satkunasivam, MD, MS, FRCSC
Muscle Invasive Urothelial Carcinoma
|
August 9, 2023
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
View More